Patents by Inventor Philippe Maria Clotaire Margaron
Philippe Maria Clotaire Margaron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240052024Abstract: A method is provided for treating a patient having a neovascular ocular disease.Type: ApplicationFiled: September 11, 2020Publication date: February 15, 2024Inventors: Margarita Gekkieva, Philippe Maria Clotaire Margaron
-
Publication number: 20140094484Abstract: The present invention relates to a rapamycin sustained release delivery system for treatment of diseases responsive to rapamycin. The sustained release delivery system of the invention includes a flowable composition containing rapamycin or a rapamycin derivative, which is capable of providing an implant containing the rapamycin or derivative thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid and rapamycin or a rapamycin derivative.Type: ApplicationFiled: October 2, 2012Publication date: April 3, 2014Applicants: QLT Inc., Tolmar Therapeutics, Inc.Inventors: Philippe Maria Clotaire Margaron, Eric Dadey, Christopher M. Lindemann, Ruihong Li
-
Patent number: 8313763Abstract: The present invention relates to a rapamycin sustained release delivery system for treatment of diseases responsive to rapamycin. The sustained release delivery system of the invention includes a flowable composition containing rapamycin or a rapamycin derivative, which is capable of providing an implant containing the rapamycin or derivative thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid and rapamycin or a rapamycin derivative.Type: GrantFiled: February 15, 2007Date of Patent: November 20, 2012Assignee: Tolmar Therapeutics, Inc.Inventors: Philippe Maria Clotaire Margaron, Eric Dadey, Christopher M. Lindemann, Ruihong Li
-
Patent number: 8106038Abstract: This invention relates generally to the field of pharmacotherapeutics and the use of photodynamic therapy (“PDT”). In particular, the invention provides a method for reducing or preventing the effects of inflammation arising from normal dose photodynamic therapy (PDT), which method comprises exposing a target tissue in a subject that has been treated with normal dose PDT treatment to low dose light having a wavelength absorbed by a photosensitizing agent used in said normal dose PDT treatment for a time sufficient to reduce or prevent the effects of inflammation arising from said normal dose PDT treatment. The method is particularly useful in reducing or preventing the effects of inflammation arising from normal dose PDT treatment of ocular tissues.Type: GrantFiled: February 15, 2002Date of Patent: January 31, 2012Assignee: QLT Inc.Inventors: Philippe Maria Clotaire Margaron, Anna M. Richter, Julia G. Levy
-
Patent number: 7122568Abstract: The present invention relates to the use of low-dose photodynamic therapy (PDT) to prevent, treat, inhibit or reduce restenosis in blood vessels. The present invention may be used in combination with any angioplastic procedure to prevent restenosis or to decrease the intima thickness, and thus luminal narrowing.Type: GrantFiled: November 17, 2000Date of Patent: October 17, 2006Assignee: QLT, Inc.Inventors: Beth Anne Allison, Philippe Maria Clotaire Margaron, Valery Rubinchik, Russell G. Hodge, Michael David Leslie Stonefield
-
Publication number: 20040208855Abstract: Long-term dialysis requires provision of safe and reliable vascular access, often in the form of an arteriovenous (AV) fistula. The primary cause of AV fistula loss or failure is stenosis caused by intimal hyperplasia (IH) in the graft at the venous anastomosis or the distal vein. Disclosed are methods of using photodynamic therapy (PDT) to inhibit IH in blood vessels which may also be used to inhibit IH and SMC growth at the anastomosis of an AV fistula in vivo.Type: ApplicationFiled: August 18, 2003Publication date: October 21, 2004Inventors: Beth Anne Allison, Philippe Maria Clotaire Margaron, York N. Hsiang
-
Patent number: 6659107Abstract: Donor material from a xenogeneic source is modified to enhance its survival time in a recipient by treating the donor material using low-dose photodynamic therapy (PDT). The donor material, such as an organ or cell suspension, is treated with a photosensitizer and irradiated in a low-dose protocol before transplantation into a xenogeneic recipient.Type: GrantFiled: March 14, 2002Date of Patent: December 9, 2003Assignees: QLT Inc., The University of British ColumbiaInventors: Modestus O. K. Obochi, Philippe Maria Clotaire Margaron, Christopher Richard Honey, Stephen Yip, Julia G. Levy
-
Patent number: 6609014Abstract: Long-term dialysis requires provision of safe and reliable vascular access, often in the form of an arteriovenous (AV) fistula. The primary cause of AV fistula loss or failure is stenosis caused by intimal hyperplasia (IH) in the graft at the venous anastomosis or the distal vein. Disclosed are methods of using photodynamic therapy (PDT) to inhibit IH in blood vessels which may also be used to inhibit IH and SMC growth at the anastomosis of an AV fistula in vivo.Type: GrantFiled: November 17, 2000Date of Patent: August 19, 2003Assignees: QLT Inc., The University of British ColumbiaInventors: Beth Anne Allison, Philippe Maria Clotaire Margaron, York N. Hsiang
-
Publication number: 20030083649Abstract: This invention relates generally to the field of pharmacotherapeutics and the use of photodynamic therapy (“PDT”). In particular, the invention provides a method for reducing or preventing the effects of inflammation arising from normal dose photodynamic therapy (PDT), which method comprises exposing a target tissue in a subject that has been treated with normal dose PDT treatment to low dose light having a wavelength absorbed by a photosensitizing agent used in said normal dose PDT treatment for a time sufficient to reduce or prevent the effects of inflammation arising from said normal dose PDT treatment. The method is particularly useful in reducing or preventing the effects of inflammation arising from normal dose PDT treatment of ocular tissues.Type: ApplicationFiled: February 15, 2002Publication date: May 1, 2003Inventors: Philippe Maria Clotaire Margaron, Anna M. Richter, Julia G. Levy
-
Publication number: 20020139938Abstract: Donor material from a xenogeneic source is modified to enhance its survival time in a recipient by treating the donor material using low-dose photodynamic therapy (PDT). The donor material, such as an organ or cell suspension, is treated with a photosensitizer and irradiated in a low-dose protocol before transplantation into a xenogeneic recipient.Type: ApplicationFiled: March 14, 2002Publication date: October 3, 2002Inventors: Modestus O.K. Obochi, Philippe Maria Clotaire Margaron, Christopher Richard Honey, Stephen Yip, Julia G. Levy
-
Publication number: 20020137676Abstract: The invention provides for the use of somatostatin receptor selective ligands (selective for SSTR1 or SSTR4) to treat human endothelial cells and to formulate medicaments for human use. The medicaments may for example be used to treat an angiogenic disease. In various embodiments, the angiogenic disease may for example be macular degeneration or a solid tumor. The SSTR1 or SSTR4 selective agonists may include the SSTR1 agonist (des-AA1,2,5 [DTrp8,IAamp9]SS).Type: ApplicationFiled: March 1, 2001Publication date: September 26, 2002Inventors: York Hsiang, Alison Buchan, Julia G. Levy, Philippe Maria Clotaire Margaron
-
Patent number: 6364907Abstract: Donor material from a xenogeneic source is modified to enhance its survival time in a recipient by treating the donor material using low-dose photodynamic therapy (PDT). The donor material, such as an organ or cell suspension, is treated with a photosensitizer and irradiated in a low-dose protocol before transplantation into a xenogeneic recipient.Type: GrantFiled: October 9, 1998Date of Patent: April 2, 2002Assignees: QLT Inc., The University of British ColumbiaInventors: Modestus O. K. Obochi, Philippe Maria Clotaire Margaron, Christopher Richard Honey, Stephen Yip, Julia G. Levy
-
Patent number: 6235767Abstract: A method to prevent or inhibit the development of arterial plaque, comprising the steps of: a. administering to a subject an amount of a green porphyrin compound effective to prevent or inhibit said development; and b. allowing the inhibition to occur in the absence of irradiation with light absorbed by the green porphyrin, or a pharmaceutical composition for preventing or inhibiting the development of arterial plaque. The composition comprises: a. an amount of a green porphyrin compound effective to prevent or inhibit the development when administered to a subject in need of such treatment, even in the absence of irradiation with light absorbed by said the green porphyrin; and b. a pharmaceutically acceptable excipient. The administration of the green porphyrin need not be accompanied by any purposeful irradiation with light.Type: GrantFiled: November 9, 1998Date of Patent: May 22, 2001Assignee: QLT, Inc.Inventors: Barbara Kelly, Julia Levy, Philippe Maria Clotaire Margaron
-
Patent number: 6117862Abstract: The invention provides a method to inhibit the formation of neovasculature while maintaining viability of the underlying tissue by subjecting a subject in which angiogenesis is to be inhibited to sublethal photodynamic therapy. The invention also provides a model for assessing sublethal PDT protocols to inhibit angiogenesis in particular target tissues.Type: GrantFiled: October 9, 1998Date of Patent: September 12, 2000Assignee: QLT, Inc.Inventors: Philippe Maria Clotaire Margaron, Simon Leong, Julia G. Levy, Anna M. Richter
-
Patent number: 5834503Abstract: A method to prevent or inhibit the development of arterial plaque, comprising the steps of:a. administering to a subject an amount of a green porphyrin compound effective to prevent or inhibit said development; andb. allowing the inhibition to occur in the absence of irradiation with light absorbed by the green porphyrin,or a pharmaceutical composition for preventing or inhibiting the development of arterial plaque. The composition comprises:a. an amount of a green porphyrin compound effective to prevent or inhibit the development when administered to a subject in need of such treatment, even in the absence of irradiation with light absorbed by said the green porphyrin; andb. a pharmaceutically acceptable excipient.The administration of the green porphyrin need not be accompanied by any purposeful irradiation with light.Type: GrantFiled: June 14, 1996Date of Patent: November 10, 1998Assignee: QLT Phototherapeutics, Inc.Inventors: Barbara Kelly, Julia Levy, Philippe Maria Clotaire Margaron